Velcade Injection, Powder, Lyophilized, For Solution
Product Images NDC 63020-049

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Velcade (NDC 63020-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Velcade 01)

Chemical structure of bortezomib, the active ingredient in VELCADE injection powder. The diagram shows the molecular arrangement, including boron and nitrogen-containing components consistent with bortezomib's known structure.*

FDA Label Image

Figure (Velcade 02)

A survival curve line chart comparing the percentage of patients over a period of 26 months for two treatment groups, Vc-MP and MP. The vertical axis shows the percentage of patients from 0 to 100, and the horizontal axis represents time in months from 0 to 26. The chart includes patient numbers at risk for each group at various time points, with a p-value from a log-rank test displayed.*

FDA Label Image

Chemical Structure (Velcade 03)

A Kaplan-Meier survival curve chart showing the percentage of patients over time (in months) comparing two treatments labeled Vc-MP and MP. The chart includes a risk table below indicating the number of patients at risk at various time points. Statistical significance is noted with a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Figure 1 (Velcade 04)

A survival curve comparing the proportion of patients over time (days) for bortezomib and dexamethasone treatments. The graph shows a higher patient proportion for bortezomib across time points, with annotations for the number of patients remaining at various days and a significant p-value (p < 0.0001) from a log-rank test.*

FDA Label Image

Figure 2 (Velcade 05)

A Kaplan-Meier survival curve depicting the proportion of patients over time (days) treated with bortezomib versus dexamethasone. The graph shows patient counts at various time points and indicates a statistically significant difference (p < 0.05) between the two treatment groups.*

FDA Label Image

Figure 3 (Velcade 06)

A Kaplan-Meier survival curve comparing the percentage of patients over time (months) for two treatment groups labeled VcR-CAP and R-CHOP. The graph includes a log rank test p-value of less than 0.001. The x-axis represents time in months up to 60, and the y-axis shows the percentage of patients up to 100. Below the graph is a table of subjects at risk for each group at various time points.*

FDA Label Image

Figure 4 (Velcade 07)

A Kaplan-Meier survival curve comparing percent of subjects alive over months from randomization between two treatment groups: VcR-CAP and R-CHOP. The graph includes a hazard ratio with 95% confidence interval. A table beneath shows the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 5 (Velcade 08)

Label for VELCADE (bortezomib) injection, powder, lyophilized for solution, 3.5 mg per vial. It is a single-dose vial intended for intravenous or subcutaneous use. The label includes storage instructions, usage directions, the product NDC 63020-049-01, and identifies Takeda Pharmaceuticals America, Inc. as the distributor.*

FDA Label Image

Logo (Velcade 09)

VELCADE (bortezomib) for Injection 3.5 mg/vial packaging label by Takeda Pharmaceuticals America, Inc. The label indicates the product is a single-dose vial for intravenous or subcutaneous use. It includes reconstitution information for subcutaneous and intravenous injections and storage instructions. The label displays NDC 63020-049-01 and notes the product is lyophilized powder for solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.